An interventional study of Shallow-Threaded Short Implant (SHI) and Shallow-Threaded Standard Implant (SDI) in Alveolar Bone Atrophy, sponsored by University of Science and Technology, Yemen. Active, not recruiting at 1 site in Yemen. Open to participants aged 18 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-09-09.
Sponsored by University of Science and Technology, Yemen · Not applicable, Interventional, and Health services research
Early Stability of Short vs. Standard Dental Implants in the Posterior Mandible
This study compares how well short dental implants (7mm) work compared to standard-length implants (11mm) when placed in the back part of the lower jaw. Both types of implants have special shallow threads designed to reduce stress on the bone. The main goal is to see how stable they are during the first 4 weeks after placement-a critical time for healing.
What will happen in the study?
Implant Placement:
Who can participate?
Adults (18-60 years) missing posterior teeth in the lower jaw, with:
How long is the study?
A prospective, controlled, parallel-group pilot clinical trial comparing 7mm short implants (SHI) versus 11mm standard implants (SDI) with identical shallow-thread macrodesign (depth \<0.5mm) and 4.2mm diameter. Implant allocation is anatomically driven based on CBCT-measured vertical bone height (7mm group: 8.5-9mm residual bone; 11mm group: ≥12.5mm).
Technical Innovations
Stability Metrics:
Bone Density Integration
Quality Controls
Rationale for 4-Week Endpoint
Focuses on the critical early healing phase where:
Technical Constraints
Innovative Aspects
First clinical study to combine:
318 studies on the registry are indexed under Alveolar Bone Loss; 79 are open to participants now.
This study's planned enrollment of 10 is below the median of 25 across 269 interventional studies indexed under Alveolar Bone Loss.
Browse Alveolar Bone Loss studies →University of Science and Technology, Yemen is the lead sponsor of 9 studies on the registry; 1 is open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
1. Uncontrolled systemic diseases (e.g., diabetes with >7%, liver disease) or medications affecting bone healing (e.g., , bisphosphonates).
2. History of head/neck radiotherapy (with in past year). 3. Heavy smoking (>10 cigarettes/day). 4. Absolute for oral surgery (e.g., recent MI/CVA \< 6months, bleeding disorders).
5. Active periodontal disease, parafunctional habits as bruxism, or prior bone grafting at the site.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Group A, Shallow-Threaded ,length 7mm, diameter 4.2mm,10 single dental implants.
Device: Shallow-Threaded Short Implant (SHI) · Device: Shallow-Threaded Standard Implant (SDI)
Group B, Shallow-Threaded ,length 11mm, diameter 4.2mm,10 single dental implants.
Device: Shallow-Threaded Short Implant (SHI) · Device: Shallow-Threaded Standard Implant (SDI)
A 7mm long, 4.2mm diameter dental implant with shallow thread (\<0.5mm depth) Macrodesign, surgically placed in the jawbone to restore missing teeth
A 11mm long, 4.2mm diameter dental implant with shallow thread (\<0.5mm depth) macrodesign, surgically placed in the jawbone to restore missing teeth.
Implant Stability Quotient (ISQ) at Baseline (T0)
Mean Resonance frequency Analysis(RFA) measurement taken immediately post-implantation(T0), to assess primary mechanical stability. ISQ range 1-100, low stability \<60, medium stability 60 to 69, high more than or equal 70. Reported as mean ISQ value per group.
Time frame: Measurement at implant placement(Day 0)
Insertion Torque value- ITV.
The rotational torque in Ncm,applied during the final quarter-turn of implant insertion. This is direct measure of primary mechanical stability. Reported as mean ITV per group.
Time frame: Measurement at during implant placement (intraoperative)
Magnitude of Stability Dip
The mean lowest point of stability curve , calculated as the greatest negative change in ISQ value from the baseline T0, measurement for each implant during the 4 -week monitoring period.
Time frame: from implant placement (Day 0) through week4
Time of Onset of Secondary Stability
The mean time in days post implantation at which the ISQ value begins to consistently increase, indicating the start biological secondary stability. Defined as the time point after the nadir -T2or T3.where the ISQ value shows a positive increase confirmed at the subsequent measurement.
Time frame: from Day0 , through week 4.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Anonymized data available upon request after publication
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report, Analytic code
Time frame: 6 months from 21/07/2025
Access criteria: De-identified individual participant data will be made available upon reasonable request to corresponding author . Requests require a methodology sound proposal and a signed data access agreement.
Started Aug 2025 (actual). Primary completion is estimated for Feb 2026, 6 months after the start.
Of 167 non-industry interventional studies with no phase under Alveolar Bone Loss, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 30. This study's planned 6 months is below that.
Counting every sponsor, half of 167 studies reached it within 18 months; a quarter within 11 and three quarters within 30.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University of Science and Technology, Yemen